Clinical trial
WEgovy Real World Assessment of Weight Loss in Korea
Invitation only · Not applicable · 1 countries · Registry ID NCT07280221
Invitation onlyNot applicableObservational
What this study is about
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age19 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity
Full registry criteria
Inclusion Criteria: 1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study. 3. Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label. 4. Male or female, aged ≥ 19 years at the time of signing the informed consent. Exclusion Criteria: 1. Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study. 2. Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice). 3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.
Treatments and study arms
Semaglutide
Drug
Semaglutide injection will be self-administered once weekly subcutaneously.
Primary outcomes
Percentage change in body weightFrom baseline (week 0) to 24 weeks
Percent (%)
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Daejeon Endo Internal Medicine Clinic🇰🇷 Daejeon, South Korea